ORYZON Reports Financial Results and Corporate Update for the 3rd Quarter Ended September 30, 2016
BARCELONA, SPAIN and CAMBRIDGE MA.
Oryzon Genomics (Madrid Stock Exchange: ORY) (ISIN Code: ES0167733015), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the third quarter of 2016 and provided an update on the Company's recent developments.